Building a New Generation AI Engine and Jointly Accelerating World-Class Innovative Drug Discovery and Development

Regor Therapeutics Group and NVIDIA Corporation today entered into collaboration that makes Regor Therapeutics Group a unique biotech company in China to have in-depth access to NVIDIA Inception. Regor Therapeutics Group will work closely with NVIDIA to integrate high performance computing technology into Regor`s proprietary Artificial Intelligence innovation platform - rCARD^TM - to accelerate the discovery and development of innovative drugs.

The NVIDIA Inception is a program designed to nurture pioneering biotech startups. In this collaboration, NVIDIA will contribute its industry-leading GPU products and high performance computing to the rCARD^TM platform, including NVIDIA Clara Discovery and the AutoDock-GPU suite. By leveraging GPU-powered parallel processing capabilities across multiple computing nodes, the rCARD^TM platform will aim to accelerate the drug discovery process, reduce R&D costs, and improve success rate of drug development. This collaboration marks another milestone in Regor`s mission to accelerate innovation and bring breakthrough innovative drugs to patients worldwide.

The rCARD^TM platform is a proprietary and highly efficient drug discovery and development platform. With foundations of scientific expertise in structural biology, computational biology and computational chemistry, the rCARD^TM platform fully integrates advanced artificial intelligence algorithms with the extensive knowledge and experiences of our seasoned drug hunters in drug research and discovery. Regor is aiming to expand the capabilities of the rCARD^TM platform and build a new generation of world-class innovative drug discovery engine through this collaboration.

"We are very excited about AI in drug discovery and its potential disruptive impacts in our industry," said Dr. Wenge Zhong, Chief Technology Officer of Regor Therapeutics Group, "Since the inception, Regor has built an interdisciplinary team of scientists and embarked on establishing the rCARD^TM platform to integrate artificial intelligence with our collective knowledge and experience in drug discovery. We are pleased to enter into this holistic collaboration with industry leader NVIDIA in AI and high performance computing to further expand and strengthen our rCARD^TM platform capabilities. We hope that together NVIDIA and Regor can help to demonstrate the power of AI in the discovery and development of innovative drugs that will benefit patients around the world."

Renee Yao, director of global healthcare startups at NVIDIA, said: "We are excited to partner with Regor Therapeutics Group to unveil a new chapter in the integration of artificial intelligence into the biopharmaceutical industry. Through this partnership, we will enable Regor to systematically enhance its HPC and AI capabilities on top of NVIDIA`s software-defined computing platform, accelerating the convergence of multidisciplinary technologies such as big data, artificial intelligence, high performance computing and innovative drug development. "

About Regor Therapeutics Group

Regor Therapeutics Group is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARD^TM (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARD^TM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.